201 related articles for article (PubMed ID: 8831043)
21. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci.
Evans PA; Norden CW; Rhoads S; Deobaldia J; Silber JL
Antimicrob Agents Chemother; 1997 Jun; 41(6):1406. PubMed ID: 9174211
[No Abstract] [Full Text] [Related]
23. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms.
Singh KV; Coque TM; Murray BE
Antimicrob Agents Chemother; 1996 Sep; 40(9):2142-6. PubMed ID: 8878596
[TBL] [Abstract][Full Text] [Related]
26. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
Yamane N; Jones RN; Frei R; Hoban DJ; Pignatari AC; Marco F
J Chemother; 1994 Apr; 6(2):83-91. PubMed ID: 8077990
[TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
[TBL] [Abstract][Full Text] [Related]
28. The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.
Hoban DJ; Jones RN; Harrell LJ; Knudson M; Sewell D
Diagn Microbiol Infect Dis; 1993; 17(2):157-61. PubMed ID: 8243037
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria.
Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL
Diagn Microbiol Infect Dis; 1991; 14(5):403-15. PubMed ID: 1665775
[TBL] [Abstract][Full Text] [Related]
30. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.
Bauernfeind A; Petermüller C
Eur J Clin Microbiol; 1982 Oct; 1(5):278-81. PubMed ID: 6223812
[TBL] [Abstract][Full Text] [Related]
33. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1996 May; 25(1):47-51. PubMed ID: 8831045
[TBL] [Abstract][Full Text] [Related]
34. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
36. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
[TBL] [Abstract][Full Text] [Related]
38. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
[TBL] [Abstract][Full Text] [Related]
39. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
40. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.
Soussy CJ; Cluzel M; Ploy MC; Kitzis MD; Morel C; Bryskier A; Courvalin P
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():43-50. PubMed ID: 10404337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
